Chronic stress, neuroendocrine disorders and metabolic syndrome;Stresul cronic, perturbǎrile neuroendocrine şi sindromul metabolic

Revista Romana de Medicina de Laborator

Volumn 19, Issue 3, 2011, Pages 219-226

  Brudaşcǎ, Ioana ^a   Cucuianu, Mircea ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Adrenergic stimulation; Cortisol secretion; Free fatty acids; Hypothalamic pituitary adrenocortical axis; Metabolic syndrome; Polycystic ovary syndrome; Stress; Visceral obesity

Indexed keywords

EID: 80355148351     PISSN: 18416624     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Moga A, Cofaru D, Pitea P, Argintaru D. Rolul unor factori endocrini şi nervoşi în patogenia aterosclerozei. Stud Cerc Med Cluj 1961; 12:77-91
2. Bjorntorp P, Rosmond R. The metabolic syndrome - a neuroendocrine disorder? Brit J Nutrition 2000; 83(suppl 1) S49-S57
3. Selye H. Syndrome produced by diverse nocuous agents. Nature 1936; 138: 32
4. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research: recent developements and applications. Psychoneuroendocrinology 1994; 19: 313-33
5. Smyth J, Ockenfels MC, Porter L, Kirschbaum C, Hellhammer DH, Stone AA. et al Stressors and mood measured on a momentary basis are associated with salivary cortisol secretion. Psychoneuroendocrinology 1998; 23: 353-70
6. Calogero AE, Gallucci WT, Gold PW, Chrousos GP. Multiple regulatory feedback loops on hypothalamic corti- cotropic releasing hormone. J Clin Invest 1988; 82(3): 767-74
7. Cucuianu M, Hǎ;rǎ;guş S, Popescu TA. Mobilizarea lipidelor, aterosclerozǎ;, hipertensiune. Clujul Medical 1969; 42(4): 581-90
8. Jacobson L, Sapolsky R. The role of the hippocampus in feeding regulation of the hypothalamic - pituitary - adrenocortical axis. EndocrRev 1991; 12:118-34
9. Herman JP, Cullinan WE. Neurocircuitry of stress control by the hypothalamic - pituitary - adrenocortical axis. Trends in Neurosci 1997; 20: 78-84
10. Eriksson E, Humble M. Serotonin in psychiatric pathophysiology in R Pohl, S Gerson (Editors). The Biological Basis for Psychopharmacological Treatment. Karger, Basel Switzerland 1990; pp 66-119
11. Akil H. Stressed and depressed. Nature Medicine 2005; 11(2): 116-18
12. Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E, Chrousos G, et al. Bone mineral density in women with depression. N Engl J Med 1996; 335: 1176-81
13. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338:171-9
14. Reaven G, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system. N Engl J Med; 1996: 334(6): 374-81
15. Brunner E, Hemingway H, Walker BR, Page M, Clarke PJ, Juneja M, et al. Adrenocortical, autonomic and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002; 106: 2659-65
16. Zhoud D, Kuznecov AW, Shurin MR, Paoli M, Rabin BS. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of the hypothalamic - pituitary - adrenocortical axis. Endocrinology 1993; 133: 2523-30
17. Mohamed Ali V, Bulmer K, Copack SW, Pinkey JH. ß adrenergic regulation of proinflammatory cytokines in humans in vivo. Endocrinology 1998; 39: 1-4 (abstract)
18. Yudkin JS, Kumari M, Humphries SE, Mohamed Ali. Inflammation, obesity, stress and coronary heart disease: is interleukin 6 the link? Atherosclerosis 2000; 148: 209-14
19. Baxter JD, McLeod KM. Molecular basis for hormone action in Bondy and Rosenberg (Editors). Metabolic Control and Disease. WB Saunders Co. Philadephia, London, Toronto, 1980 pp104-160
20. Fray KN. Metabolic regulation. A human perspective. Blackwell Science Ltd 2003
21. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to nonfat cells. Vitam Horm 2006; 74: 443-77
22. Lonnqvist F, Thorne A, Nilsell K, Hoffsted J, Arner P. A pathogenic role of visceral fat beta 3 adrenoceptors in obesity. J Clin Invest 1995, 95:1109-16
23. Hui J, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. et al Beyond insulin resistance in NASH: TNFα or adiponectin. Hepatology 2004; 40(1):46-54
24. Brudaşč I, Cucuianu M: Pathogenic role of abnormal free fatty acids and adipokines in the portal flow. Relevance for the metabolic syndrome, hepatic steatosis and steatohep- atitis. Rom J Int Med 2007; 45(2):149-57
25. Desbriere R, Vuaroqueaux V, Achard V, Boullu Ciocca S, Labuhn M, Dutour A, et al. 11ß hydroxysteroid dehydrogenase tpe 1 mRNA is increased in both visceral and subcutaneous adipose tissue in obese patients. Obesity 2006; 14(5):794-8
26. Ganong WF. Origin of angiotensin II secreted by cells. Proc Soc Exp Biol Med 1994; 205:213-19
27. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlson B, Carlsson LM. et al Human adipose tissue expresses angiotensinogen and enyzmes required for its conversion to angiotensin II. J Clin Endocrinol Metabol 1998; 83:3925-9
28. Mallow H, Trindle A, Loffler G. Production of angiotensin II receptor type one (AT 1) and type two (AT 2) during the differentiation of 373-L1 preadipocytes. Horm Metab Res 2000; 32: 500-3
29. Fuller P. Aldosterone secretion. Chapter 99 In Jameson IL and De Groot LJ. Endocrinology Saunders Elsevier 6th edition 2010; 1831-8
30. Suzuki H. Eguchi S. Adiponectin versus angiotensin II: key pathological role of their misbalance. Kidney International 2006; 70: 1717-24
31. Fruchard JC, Duriez P, Staels B. Peroxysome proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999; 10: 245-67
32. Drevon CA. Fatty acids and expression of adipokines. Biochem Biophys Acta 2005;1740: 287-92
33. Schneider DJ, Sobel BE. Synergic augmentation of PAI-1 mRNA in culture of HepG2 cells. Coron Artery Dis 1996; 7: 866-71
34. Chen YB, Billadello JJ, Schneider DJ. Identification and localization of fatty acids response region in the human PAI-1 gene. Arterioscler Thromb Vasc Biol 2000; 20:2697-701
35. Steneberg P, Rubins N, Bartoov-Schifman R, Walker MD, Edlung H, The FFA receptor GPR 40 links hyperinsu- linemia, hepatosteatosis and impaired glucosis homeostasis in mouse. Cell Metabolism 2005; 1:245-58
36. Medina Gomez G, Vidal Puig A. Gateway to the metabolic syndrome. Nature Medicine 2005; 11(6): 602-3
37. Carpentier A, Mittelman SD, Lamarche B, Giacca A, Lewis GF. Acute enhancement of insulin secretion by FFA in human is lost with prolonged FFA elevation. Am J Physiol Endocrinol Metabol 1999; 276:1055-66
38. Kahn SE. The importance of ß cell failure in the development and progression of type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2001; 86(9):4047-58
39. Ionescu Târgovişte C. For a new paradigm in diabetes. Rom J Int Med 2007; 45(1):3-15
40. Kicklighter EJ, Kulkami B. The gonads. Chapter 41 in Kaplan Pesce (Editors). Clinical Chemistry CW Mosby Company St. Louis- Toronto-Princeton 1984, pp789-805
41. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insuline resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356-9
42. Kiddy DS, Hamilton Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, et al. Improvement of endocrine and ovarian function during dietary treatment of obese women with polycystic ovarian syndrome. Clinical Endocrinology 1992; 36: 105-11
43. Lee PJ, Patel A, Hindmarch PC, Mowat AP, Leonard JV. The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyperinsulin- ism. Clinical Endocrinology 1995; 42:601-6
44. Oehler G, Mathes KJ. Hyperinsulinemia in hepatic steatosis. International Journal of Obesity 1982; 6(suppl 1): 137-44
45. Rutkowski P, Klassen A, Sebekova K, Bahner U, Heidland A. Renal disease in obesity: the need for greater attention. J Renal Nutrition 2006; 16: 216-223
46. Avancini Caramoni ML, Rossing P, Mauer M. Diabetic nephropathy. In Jameson and De Groot (editors). Endocrinology 2006: pp 999-1036
47. Despres JP, Golay A, Sjostrom L. Rimonabant in obesity. Lipid Study Group. Effects of rimonabant on metabolic risk factors. N Engl J Med 2005; 353: 2121-34
48. Mitchell BP, Morriss MJ. Depression and anxiety with rimonabant. Editorial. Lancet 2007; 370: 1671-2
49. Paul-Labrador M, Polk D, Dwyer JD, Velasquez J, Nidich S, Rainforth M, et al. Effects of a randomized control trial of transcendental meditation on compounds of the metabolic syndrome in subjects with coronary heart disease. Arch Int Med 2006; 106: 1218-24
50. Francis GS. ACE inhibition in cardiovascular disease. Editorial. N Engl J Med 2011; 342(3): 201-2
51. Brunner EJ, Marmot MG, Nanchahal K, Shipley MJ, Stanfield A, Juneja M, et al. Social inequality in coronary risk; central obesity and the metabolic syndrome: evidence from the Whitehall II sudy. Diabetologia 1997; 40: 1341-9
52. Marmot MG. Inequality in health. N Engl J Med 2001; 345: 134-6